Capital Fund Management (CFM)
AVIR icon

Capital Fund Management (CFM)’s Atea Pharmaceuticals AVIR Stock Holding History

Capital Fund Management (CFM)’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-35,565
Closed -$257K – 1415
2022
Q1 		$257K Buy
+35,565
New +$242K ﹤0.01% 1393

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Capital Fund Management (CFM)'s AVIR Position: Q2 2022 in Review

Capital Fund Management (CFM) sold out of Atea Pharmaceuticals (AVIR) in Q2 2022, closing a stake of 35,565 shares — an estimated $257K sold.

Capital Fund Management (CFM) first reported a position in AVIR in Q1 2022 and held it in 1 quarter. The position peaked at $257K in Q1 2022. 127 funds tracked by Wall St. Rank hold AVIR as of Q2 2022.

  • Capital Fund Management (CFM) reported no remaining Atea Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 35,565 Atea Pharmaceuticals shares in Q2 2022, an estimated $257K.
  • Capital Fund Management (CFM) first reported a position in Atea Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Capital Fund Management (CFM)'s Atea Pharmaceuticals position peaked at $257K in Q1 2022.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2022.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2022, filed 12 Aug 2022.